Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Results of Operations and Financial Condition
26 Apr 24
8-K
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
8-K
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
15 Mar 24
8-K
Other Events
8 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
8-K
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
23 Jan 24
8-K
Other Events
8 Dec 23
UPLOAD
Letter from SEC
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
9 Nov 23
8-K
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
20 Oct 23
CORRESP
Correspondence with SEC
4 Oct 23
8-K
Other Events
21 Sep 23
UPLOAD
Letter from SEC
21 Sep 23
8-K
Termination of a Material Definitive Agreement
19 Sep 23
8-K
Results of Operations and Financial Condition
29 Aug 23
CORRESP
Correspondence with SEC
21 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
2 Aug 23
CORRESP
Correspondence with SEC
26 Jul 23
8-K
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
24 Jul 23
UPLOAD
Letter from SEC
21 Jul 23
8-K
Termination of a Material Definitive Agreement
11 Jul 23
8-K
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
15 Jun 23
8-K
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
26 May 23
S-3ASR
Automatic shelf registration
9 May 23
S-3ASR
Automatic shelf registration
9 May 23
8-K
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
8 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Results of Operations and Financial Condition
25 Apr 23
8-K
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or
20 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
Latest ownership filings
4
JOHN OYLER
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
3
Titus B. Ball
26 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
4
JOHN OYLER
14 Mar 24
4
Donald W. Glazer
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
OLIVIER BRANDICOURT
4 Mar 24
4
Julia Aijun Wang
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
SC 13G/A
Capital International Investors
9 Feb 24
SC 13G/A
OYLER JOHN
5 Feb 24
3
OLIVIER BRANDICOURT
23 Jan 24
4
Xiaodong Wang
4 Dec 23
144
Notice of proposed sale of securities
14 Nov 23
144
Notice of proposed sale of securities
14 Nov 23
4
JULIAN BAKER
14 Nov 23
SC 13D/A
BAKER BROS. ADVISORS LP
14 Nov 23
144
Notice of proposed sale of securities
13 Nov 23
4
Chan Henry Lee
2 Aug 23
144
Notice of proposed sale of securities
31 Jul 23
4
Julia Aijun Wang
6 Jul 23
144
Notice of proposed sale of securities
3 Jul 23
4
Lai Wang
27 Jun 23
4
Julia Aijun Wang
27 Jun 23
4
Corazon (Corsee) D. Sanders
27 Jun 23
4
Xiaobin Wu
27 Jun 23
144
Notice of proposed sale of securities
26 Jun 23
144
Notice of proposed sale of securities
26 Jun 23
144
Notice of proposed sale of securities
23 Jun 23
144
Notice of proposed sale of securities
23 Jun 23
4
Corazon (Corsee) D. Sanders
20 Jun 23
4
Alessandro Riva
20 Jun 23
4
Thomas Malley
20 Jun 23
4
ANTHONY C HOOPER
20 Jun 23
4
Donald W. Glazer
20 Jun 23
4
Chan Henry Lee
20 Jun 23
4
Lai Wang
20 Jun 23
4
JULIAN BAKER
20 Jun 23
4
Qingqing Yi
20 Jun 23